Zhejiang Bio released its 2026 interim report. Total operating revenue was 53.3882 million yuan, down 10.55% year on year. Net profit attributable to the parent company was negative 40.5894 million yuan, a decrease of 30.7384 million yuan compared with the same period last year, with the loss widening. Net cash inflow from operating activities was 11.6042 million yuan, down 55.06% year on year. The company's asset-liability ratio was 10.82%, gross margin was 65.05%, return on equity was negative 1.24%, and diluted earnings per share was negative 0.23 yuan. The number of shareholders was 14,000, and the top ten shareholders held 42.87% of the total share capital.
Shanghai ZJ Bio-Tech Co. Ltd. ANet loss widened to 40.59 million yuan with revenue down 10.55%.
